These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35070493)

  • 1. Primidone Intolerance in Essential tremor: Is it More than Just Age?
    Lenka A; Louis ED
    Tremor Other Hyperkinet Mov (N Y); 2021; 11():57. PubMed ID: 35070493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19 polymorphism and risk for essential tremor.
    Alonso-Navarro H; Martínez C; García-Martín E; Benito-León J; García-Ferrer I; Vázquez-Torres P; Puertas I; López-Alburquerque T; Agúndez JA; Jiménez-Jiménez FJ
    Eur Neurol; 2006; 56(2):119-23. PubMed ID: 16960452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Primidone on Dentate Nucleus γ-Aminobutyric Acid Concentration in Patients With Essential Tremor.
    Louis ED; Hernandez N; Dyke JP; Ma R; Dydak U
    Clin Neuropharmacol; 2016; 39(1):24-8. PubMed ID: 26757316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of primidone in essential tremor.
    Koller WC; Royse VL
    Neurology; 1986 Jan; 36(1):121-4. PubMed ID: 3941767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupuytren, Ledderhose, and Peyronie Diseases After Primidone Use For Essential Tremor.
    Vasconcellos LFR; Nassif D; Spitz M
    Neurologist; 2019 Sep; 24(5):150-151. PubMed ID: 31478998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential for Intrathecal Baclofen in Treatment of Essential Tremor.
    Hamad M; Holland R; Kamal N; Luceri R; Mammis A
    World Neurosurg; 2017 Sep; 105():170-175. PubMed ID: 28559069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, longitudinal analysis of medication use in a cohort of elderly essential tremor cases.
    Delgado N; Berry DS; Hernandez DI; Louis ED
    J Neurol Sci; 2022 Nov; 442():120387. PubMed ID: 36041330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide.
    Gunal DI; Afşar N; Bekiroglu N; Aktan S
    Neurol Sci; 2000 Oct; 21(5):315-7. PubMed ID: 11286044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and electromyographic assessment of essential tremor treatment.
    Milanov I
    Parkinsonism Relat Disord; 2002 Jun; 8(5):343-8. PubMed ID: 15177063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of medication usage patterns among essential tremor patients: movement disorder specialists vs. general neurologists.
    Diaz NL; Louis ED
    Parkinsonism Relat Disord; 2010 Nov; 16(9):604-7. PubMed ID: 20691629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and chronic effects of propranolol and primidone in essential tremor.
    Koller WC; Vetere-Overfield B
    Neurology; 1989 Dec; 39(12):1587-8. PubMed ID: 2586774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.
    Alonso-Navarro H; García-Martín E; Agúndez JAG; Jiménez-Jiménez FJ
    Curr Neuropharmacol; 2020; 18(6):518-537. PubMed ID: 31976837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial comparing primidone initiation schedules for treating essential tremor.
    O'Suilleabhain P; Dewey RB
    Mov Disord; 2002 Mar; 17(2):382-6. PubMed ID: 11921128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spastic dysphonia and essential (voice) tremor treated with primidone.
    Hartman DE; Vishwanat B
    Arch Otolaryngol; 1984 Jun; 110(6):394-7. PubMed ID: 6721782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up.
    Serrano-Dueñas M
    Parkinsonism Relat Disord; 2003 Oct; 10(1):29-33. PubMed ID: 14499204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primidone in essential tremor of the hands and head: a double blind controlled clinical study.
    Findley LJ; Cleeves L; Calzetti S
    J Neurol Neurosurg Psychiatry; 1985 Sep; 48(9):911-5. PubMed ID: 3900296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of pharmacological treatments for essential tremor.
    Lyons KE; Pahwa R; Comella CL; Eisa MS; Elble RJ; Fahn S; Jankovic J; Juncos JL; Koller WC; Ondo WG; Sethi KD; Stern MB; Tanner CM; Tintner R; Watts RL
    Drug Saf; 2003; 26(7):461-81. PubMed ID: 12735785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing GABA inhibition is the next generation of medications for essential tremor.
    Ondo W
    Int Rev Neurobiol; 2022; 163():317-334. PubMed ID: 35750368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Patterns in Essential Tremor: A Retrospective Analysis.
    Shah C; Jackson GR; Sarwar AI; Mandava P; Jamal F
    Tremor Other Hyperkinet Mov (N Y); 2022; 12():10. PubMed ID: 35415009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits and risks of pharmacological and surgical treatments for essential tremor: disease mechanisms and current management.
    Rincon F; Louis ED
    Expert Opin Drug Saf; 2005 Sep; 4(5):899-913. PubMed ID: 16111452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.